emeis in the news

Emeis stock saw a modest 2.1% rebound to 10.23 euros after significant declines, with the company recently completing its withdrawal from Latin America and raising its full-year guidance.

Emeis sold its Latin American operations for 111 million Euros.

This is a transcript of emeis's Q1 FY2026 earnings call hosted by Jean-Marc Boursier and Samuel Henry Diesbach.

emeis finalized the divestment of all its operating activities in Latin America for ‑111m, marking a strategic repositioning towards European markets and strengthening its financial structure.

Emeis has completed its withdrawal from Latin America, divesting assets for approximately –111M to strategically reposition in European markets.

Emeis completed its exit from Latin America by selling its Brazilian operations as part of a 2024 divestment plan, resulting in an accretive effect and contributing to deleveraging.

Emeis completed the sale of its Latin American operations for approximately ‑111 million.

Emeis stock plummets by over 23% in one month and reaches an extreme oversold state despite the company's positive first-half 2026 results and raised guidance, amid concerns about French public finances.

Emeis's share price plummeted by over 22% in the last month, falling to €10.20 due to broader French public finance tensions and rising interest rates, despite positive half-year results.

The document states the tangible book value per share for Emeis (HAN:OPA1), with copyright by the American Bankers Association and CUSIP data from FactSet Research Systems Inc.

Emeis shares are declining, breaking below a key support level despite the company's upward revision of its 2026 annual guidance.

Emeis SA operates geriatric healthcare facilities globally, offering nursing homes, psychiatric care, home care, and rehabilitation clinics.

Emeis stock rebounded by 2.35% today, contrasting with a broader market decline, despite recent losses and technical indicators suggesting continued resistance.

Emeis shares experienced a significant decline, threatening a key support level despite recent operational growth.

Emeis conducted share buybacks in August 2026, repurchasing 100,000 shares to optimize capital and support its stock price, reflecting confidence in its mission-driven transformation within the European health and care sector.

Emeis shares gained 2.67% to €13.06, placing it among the top SBF 120 performers, though its technical configuration remains fragile despite recent organic growth.

Emeis has filed its 2026 Half-Year Financial Report, detailing its operations in health, care, and support for the frail across 19 countries, and its recent commitment as a mission-driven company.

Emeis hosted a conference call to review its half-year results for 2026, structured in two parts.

emeis Société anonyme is still loss-making in H1 2026 despite revenue growth and asset disposals, with its stock reflecting ongoing profitability concerns.

Emeis has released its half-year financial report for the first six months of 2026, highlighting its operations in healthcare and social care across 19 countries.